Effectiveness of omalizumab in reducing corticosteroid burden in patients with moderate to severe persistent allergic asthma

The addition of omalizumab to baseline therapy in patients 12 years or older with moderate to severe persistent allergic asthma resulted in a durable reduction in the overall steroid burden and improvement in other clinical measures of asthma control.